Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-Negative Breast Cancer × anlotinib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 5 Pancreatic Neoplasms 1 HER2-Negative Breast Cancer 1 Cholangiocarcinoma 1 Breast Neoplasm Female 1

Interventions

pembrolizumab 1 anlotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07396454 2026-02-09

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting

HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡